Fintech PR

Global Securities Brokerage & Stock Exchange Services Market Size Expected to Reach $1.84 Trillion In 2023

Published

11 months ago

November 30, 2023

*No Investment Advice Provided*

PALM BEACH, Fla., Nov. 30, 2023 /PRNewswire/ — Stock brokerage is a financial organization on the stock or commodity markets who buys and sells assets in the client’s best interest for which brokerage fee is charged. A stock exchange is a standardized and authorized marketplace where stockbrokers and traders can buy and sell stocks, bonds, and other securities. The services are offered through various modes, such as online and online modes. The various establishments involved are exclusive brokers, banks, investment firms, and other establishments. The securities brokerage and stock exchange services market consist of revenues earned by entities by acting as brokers in selling securities such as equities, bonds, commodities and derivatives. Securities brokerages represent customers in dealing with securities transactions on the trading floor/online platform of stock exchanges. The securities brokerages might sometimes act as a representative for both buyer and seller. This market excludes the advisory and investment activities of the brokerage firms. This market includes transaction charges levied by stock exchanges for trading on its trading floor/online platform to securities brokerages and other fees. It does not include the value of the funds invested in securities. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The rise in the use of AI for faster trade executions is the main driver of the market. A report from The Business Research Company projected that the global securities brokerage and stock exchange services market size grew from $1696.91 Billion in 2022 to $1844.31 Billion in 2023 at a compound annual growth rate (CAGR) of 8.7%. The market size of global securities brokerage and stock exchange services market is expected to grow to $2506.41 billion in 2027 at a CAGR of 8.0%. Mentioned in today’s coverage includes: EF Hutton, JPMorgan Chase & Co. (NYSE: JPM), Jefferies Financial Group Inc. (NYSE: JEF), Goldman Sachs (NYSE: GS), Bank of America Corporation (NYSE: BAC), Citigroup Inc. (NYSE: C).

The report added: “Securities brokerage companies are extensively using artificial intelligence for faster trade executions. Artificial intelligence refers to programming machines to enable them to work and react like humans. Most companies are using AI for algorithmic trading in stock brokerage. Algorithmic trading refers to turning a trading idea into an algorithmic trading strategy using an algorithm. The AI-enabled alternative trading system (ATS) helps in improving the speed of trade execution. North America was the largest region in the securities brokerage and stock exchange services market size in 2022. South America was the second largest region in the securities brokerage and stock exchange services.”

EF Hutton Completes Acquisition of Broker-Dealer Benchmark Investments, LLC – EF Hutton, an investment bank headquartered in New York, today announced the closing of the acquisition of its broker-dealer, Benchmark Investments, LLC, a provider of a range of financial services to institutional and retail clients.

The transaction closed on November 9, 2023, significantly expanding EF Hutton’s capabilities and leadership across public and private markets for its growing roster of clients, with all broker-dealer resources and operations to be held under the EF Hutton brand. Benchmark Investments, LLC name has been changed to “EF Hutton LLC.” Additional details of the transaction were not disclosed.

“This transformative acquisition is the next step in our evolution to help our clients’ ambitions prosper through a full spectrum of services,” said Joseph T. Rallo, Chief Executive Officer of EF Hutton. “Looking ahead, we are integrating broker-dealer operations and believe this transaction will enhance our current business lines with the capacity for larger deals and a broader client base, while also providing a platform to expand our business lines in the future. We continue to look for additional opportunities to bolster our services and strengthen our footprint, including the expansion of our retail business through our wealth management division,” concluded Rallo.

David W. Boral, President of EF Hutton, added, “Incorporating broker-dealer functions and services into the firm will bring a higher degree of streamlined operations and efficiency for our clients. This acquisition also provides us with additional independence that gives more control and transparency to the deal process from start to finish. Our improved end-to-end solutions will position clients for long-term success across IPOs, SPAC IPOs, follow-on offerings, secondary offerings, shelf takedowns, M&A, advisory, acquisition financings, pre-IPO financings, and more. We look forward to introducing middle market and emerging growth companies around the world to an expanded EF Hutton.” For more information on EF Hutton, please visit: https://efhutton.com/ef-hutton-news/

Other recent developments in the financial markets of note include:

JPMorgan Chase & Co. (NYSE: JPM) recently kicked off its second annual DEVUP, a firmwide software engineering conference designed for engineers by engineers. Launched in 2022, DEVUP is a one-of-a-kind technology innovation forum convening more than 500 software engineers, data scientists and other technologists from all 23 of the financial services firm’s Global Technology Centers for three days of programming that celebrate engineering excellence.

The agenda features wide-ranging discussions on cutting-edge research, interactive workshops, and hands-on experiences led by more than 150 speakers. Participants have the unique opportunity to showcase and learn skills, build connections with peers, and discuss new ways to implement emerging technologies at massive scale and speed at one of the world’s large financial institutions.

“In today’s dynamic technology landscape, the role of the software engineer – and the technologist more broadly – is undergoing a transformative shift. DEVUP is an opportunity to recognize JPMorgan Chase’s top software engineers, provide experiences for them to build their skills, and foster a sense of community – all with the aim of empowering them to continue driving innovation across our firm,” said Lori Beer, Global Chief Information Officer, JPMorgan Chase. “Already a beloved tradition among JPMorgan Chase’s technologists in its second year, DEVUP brings together our software engineers from across the world to explore opportunities for innovation and impact, and champion the broader firm’s technology-forward mindset.”

Bank of America Corporation (NYSE: BAC) Chair and Chief Executive Officer Brian Moynihan will participate in the Goldman Sachs 2023 US Financial Services Conference on Tuesday, December 5, at 9:20 a.m. ET. A live webcast of this event will be accessible through the Bank of America Investor Relations website at https://investor.bankofamerica.com.

Citigroup Inc. (NYSE: C) – Citibank is launching its first football promotional campaign in Singapore, giving its customers a once-in-a-lifetime opportunity to attend the prestigious UEFA Champions League Final live in London.

The global bank is the first in Singapore to partner Mastercard for the 2023/24 UEFA Champions League, responding to the passion points of its clients and the intense popularity of football in the region.

Regina Lim, Citibank Singapore Head of Credit Cards and Personal Loans, said: “Customers want a win-win relationship with a bank that understands and empowers them to pursue their passion. Given the immense following football has in Singapore, this campaign exemplifies our commitment to be the bank that gets our customers ahead and delivers exceptional value for them.

Jefferies Financial Group Inc. (NYSE: JEF) Richard Handler, CEO, and Brian Friedman, President recently released a statement regarding the firm’s Q3 Financial highlights.

“Our third quarter net revenues of $1.18 billion reflect an improving market environment. We are increasingly optimistic that we have come off the bottom of the cycle and that momentum in investment banking will continue.

“Investment Banking generated $645 million of net revenues, an increase of 28% from last quarter due to modestly improved mergers and acquisitions activity and a more receptive leveraged finance and new issue market, as the green shoots we mentioned last quarter have multiplied.”

“Our strategy during down cycles has always been to play offense by investing in our future. This is the main theme for us in 2023, made possible by our strong capital base and solid global brand and platform. The dislocation and changes in strategy among some of our competitors created distinct opportunity this year. As we will discuss during our upcoming Investor Day on October 16, 2023, we are adding outstanding new Managing Directors to our Investment Banking effort across the globe. We started 2023 with 299 Managing Directors in Investment Banking and expect to begin 2024 with over 360 total Managing Directors, an increase of 20%. The 360 Managing Directors would be up 70% from the 212 Investment Banking Managing Directors that wore the Jefferies’ jersey at the beginning of 2020.”

Goldman Sachs (NYSE: GS) recently recognized CEO of 6sense, Jason Zintak, as one of the Most Exceptional Entrepreneurs of 2023 at its Builders and Innovators Summit in Healdsburg, California. Goldman Sachs selected Zintak from multiple industries honored at the two-day event. Since Zintak joined 6sense in 2017, the company has grown astronomically by every measure: employee, customer, net revenue retention, and revenue growth. With a reputation for making smart moves, prioritizing people, and creating a culture of innovation, Zintak leads the company towards its mission to revolutionize the way B2B organizations create, manage and convert pipeline to revenue.

“To be recognized for entrepreneurship by Goldman Sachs is an incredible honor,” said Jason Zintak, 6sense CEO. “This recognition reflects the strength and passion of our team and our commitment to a growth mindset which fosters ongoing learning, curiosity and innovation. Our collective entrepreneurial spirit at 6sense started with our founders and leaders and continues today across the organization as a defining element of our success in delivering real value to our customers.”

About FN Media Group:

At FN Media Group, via our top-rated online news portal at www.financialnewsmedia.com, we are one of the very few select firms providing top tier one syndicated news distribution, targeted ticker tag press releases and stock market news coverage for today’s emerging companies.

Follow us on Facebook to receive emerging news updates: https://www.facebook.com/financialnewsmedia.
Follow us on Twitter for real time Breaking News: https://twitter.com/FNMgroup.
Follow and us on LinkedIn: https://www.linkedin.com/in/financialnewsmedia/.

DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM expects to be compensated twenty six hundred dollars for news coverage of the current press releases issued by Homerun Resources Inc. by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:
Media Contact email: [email protected]; +1(561)325-8757

View original content:https://www.prnewswire.co.uk/news-releases/global-securities-brokerage–stock-exchange-services-market-size-expected-to-reach-1-84-trillion-in-2023–302001960.html

Fintech PR

Reshaping Finance: Huawei’s Commitment to 4-Zero and Resilient Infrastructure

Published

6 hours ago

October 15, 2024

CISION (PR Newswire)

reshaping-finance:-huawei’s-commitment-to-4-zero-and-resilient-infrastructure

DUBAI, UAE, Oct. 15, 2024 /PRNewswire/ — On the first day of GITEX GLOBAL 2024, the Huawei Finance Forum was held under the theme of Boost Resilience, Reshaping Smarter Finance Together. This forum explored how to build resilient financial infrastructure for the future, as well as digital transformation and ecosystem development to help financial institutions gain a new competitive edge.

Over the past 15 years, China’s finance industry has undergone a significant transformation, largely driven by FinTech giants. As Chinese banks embarked on their digital transformation journey, Huawei developed an FSI solution framework, which focuses on reshaping customers’ resilience, agility, and intelligence.

“The value Huawei brings to our customers is not only in our products and solutions, but also in our unique capabilities, such as best practices worldwide, a global ecosystem, and an extensive digital talent system in China. These capabilities are crucial for customers’ successful transformation.” Shared by Alvin Feng, Director of Global Marketing and Solution Sales, Huawei Digital Finance BU.

Huawei has proposed reshaping resilient financial infrastructure with 4 Zeros: Zero Downtime, Zero Wait, Zero Touch, and Zero Trust. To achieve this, we need to coordinate cloud, network, storage, and computing infrastructure to develop an end-to-end resilient system.

Application modernization is vital for reshaping agility. Huawei has successfully supported many banks in transforming their legacy centralized architecture towards a cloud-native distributed architecture.

In terms of reshaping intelligence. Huawei supports banks in enhancing real-time data operations, a fundamental step for data intelligence. Meanwhile, we actively boost Generative AI adoption in banks through joint innovations in various scenarios.

Dr. Jassim Haji, President of the International Group of Artificial Intelligence, Executive Advisor of HH (His Highness) Nasser Artificial Intelligence Research and Development Center.

“Huawei is pioneering the future of intelligent finance, seamlessly blending AI innovation with enduring infrastructure. Their vision for All Intelligence and commitment to building resilient, secure, and efficient financial ecosystems is transforming the industry, creating smarter, more inclusive services for the AI era.” Said Dr. Jassim Haji, President of the International Group of Artificial Intelligence, Executive Advisor of HH (His Highness) Nasser Artificial Intelligence Research and Development Center.

Roger Wang, Director of Partner Development & Sales, Digital Finance BU, Huawei

“Huawei is continuously collaborating with global and local ecosystem partners to deliver value to customers by developing competitive scenario-based solutions”, stated by Roger Wang, Director of Partner Development & Sales, Digital Finance BU, Huawei. We consistently add value to our customers’ success through our global best practices, business and architecture innovation, and excellent service and support.

For more details, please visit: https://e.huawei.com/en/industries/finance

Photo – https://mma.prnewswire.com/media/2531210/image_986294_58657447.jpg
Photo – https://mma.prnewswire.com/media/2531211/image_986294_58657478.jpg
Photo – https://mma.prnewswire.com/media/2531212/1.jpg

View original content:https://www.prnewswire.co.uk/news-releases/reshaping-finance-huaweis-commitment-to-4-zero-and-resilient-infrastructure-302276872.html

Fintech PR

Qatari Diar Unveils Exclusive Waterfront Townhouses at The Seef Lusail

Published

9 hours ago

October 15, 2024

CISION (PR Newswire)

qatari-diar-unveils-exclusive-waterfront-townhouses-at-the-seef-lusail

Luxury Living Redefined with Attractive Investment Opportunities Starting from QAR 1.7 Million for apartments and QAR 3.4 Million for townhouses in Downtown Lusail

Flexible Payment Plans with 0% Interest and Direct Financing

Freehold Ownership and Residency in Qatar

DOHA, Qatar, Oct. 15, 2024 /PRNewswire/ — Qatari Diar Real Estate Investment Company announced the launch of exclusive upscale waterfront townhouses at The Seef in Downtown Lusail, offering exceptional investment opportunities with 0% interest, direct financing, and flexible payment plans. Lusail represents a bold step forward in sustainable, smart urban living. Known for its state-of-the-art infrastructure and forward-thinking design, Lusail offers a mix of residential, commercial, and entertainment districts just minutes from Qatar’s newest community.

Situated in the heart of Lusail’s waterfront district, The Seef offers a limited collection of luxurious townhouses starting from QAR 3.4 million and apartments starting from QAR 1.7 million. These residences offer immediate occupancy and are designed to provide residents with a blend of modern elegance and comfort. With breathtaking sea views overlooking Qetaifan Islands and Lusail’s iconic skyline, the townhouses redefine modern living.

Lusail’s thriving real estate market presents significant growth potential for investors. The Seef offers freehold ownership, providing residency in Qatar for foreigners. With mortgage financing options from leading local banks, in addition to direct payment plans with 0% interest extending to 6 years for apartments and 4 years for townhouses, owning a luxury residence in The Seef is more accessible than ever. Situated in a location known for attracting substantial foreign investment, The Seef promises robust returns whether for resale or long-term residence.

Eng. Ali Mohamed Al-Ali, CEO of Qatari Diar, said: “The launch of our exclusive waterfront townhouses at The Seef marks a significant milestone in offering unparalleled luxury living in Qatar. Lusail represents more than just a place to live; it’s a lifestyle destination that combines convenience, sophistication and investment potential. With the recent advancements in the Qatari mortgage law, we are thrilled to extend flexible financing options in partnership with several Qatari banks that make owning a piece of this vibrant community achievable for a broader market.”

The Seef’s townhouses are built to meet the diverse needs of residents, from professionals to families. Each townhouse features spacious layouts with high-end finishes, ensuring comfort and luxury at every turn. Residents will enjoy uninterrupted sea views, offering a tranquil escape within the city, and lush green landscapes that create a serene environment for relaxation. The prime location provides proximity to key attractions, including the Meryal Waterpark—the largest in Qatar—Lusail Marina, and Place Vendôme. Located near transit hubs, major highways, shopping centers, healthcare facilities, and educational institutions, The Seef offers residents unparalleled convenience, placing all the vibrant energy of Lusail right at their doorstep.

The Seef reflects Qatari Diar’s commitment to sustainability, with eco-friendly design elements that include energy-efficient infrastructure and green landscaping. The project’s unique architectural innovations, including sky bridge swimming pools and modern areas amenities, such as kids’ playgrounds, squash courts, gym facilities, retail outlets, and serene promenades, sets it apart from typical residential projects, creating a true lifestyle destination.

Prospective buyers and investors are invited to explore The Seef firsthand at the Cityscape Global in Riyadh, Saudi Arabia from 11 – 14 November. Attendees will have the opportunity to learn more about the development, view its luxury offerings, and discover how The Seef can become part of their future in Lusail, Qatar’s city of the future.

For more information, please visit Qatari Diar’s website to explore The Seef and view the full portfolio of investment opportunities.

About Qatari Diar
Qatari Diar Real Estate Company was established in 2005 by the Qatar Investment Authority, the sovereign wealth fund of the State of Qatar. Headquartered northeast of capital, Doha, in the City of Lusail, on the coast of the Arabian Gulf. Qatari Diar was entrusted to support Qatar’s growing economy and to coordinate the country’s real estate development priorities. For more information, visit qataridiar.com.

Logo – https://mma.prnewswire.com/media/2531093/Qatari_Diar_Logo.jpg
Photo – https://mma.prnewswire.com/media/2531089/Qatari_Diar_Seef.jpg
Photo – https://mma.prnewswire.com/media/2531090/Qatari_Diar_Lusail.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/qatari-diar-unveils-exclusive-waterfront-townhouses-at-the-seef-lusail-302276626.html

Fintech PR

PharmaMar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Published

9 hours ago

October 15, 2024

CISION (PR Newswire)

pharmamar-announces-positive-and-statistically-significant-overall-survival-and-progression-free-survival-results-for-zepzelca-(lurbinectedin)-and-atezolizumab-combination-in-first-line-maintenance-therapy-for-extensive-stage-small-cell-lung-cancer

Jazz plans to submit supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) and PharmaMar will submit Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) in first half of the year 2025 for this combination therapy as a first-line maintenance treatment for ES-SCLC.

MADRID, Oct. 15, 2024 /PRNewswire/ — PharmaMar (MSE: PHM) and its partner Jazz Pharmaceuticals plc (Nasdaq: JAZZ) have announced today positive top-line results from the Phase 3 clinical trial evaluating Zepzelca^® (lurbinectedin) in combination with the PD-L1 inhibitor atezolizumab (Tecentriq^®) compared to atezolizumab alone when administered as a maintenance treatment for adults with extensive-stage Small Cell Lung Cancer (ES-SCLC) following induction therapy with carboplatin, etoposide and atezolizumab. The combination of lurbinectedin and atezolizumab demonstrated a statistically significant improvement in the primary endpoints of overall survival (OS) and progression-free survival (PFS), as assessed by an independent review facility (IRF), compared to treatment with atezolizumab alone.

“Each year, approximately 63,000 to 72,000 new cases of Small Cell Lung Cancer (SCLC) are reported in Europe. A majority of these patients are diagnosed with extensive stage disease, which is aggressive and often difficult to treat, with poor prognosis,[i]^,[ii]^,[iii]” said Luis Paz-Ares, M.D., Ph.D., head of medical oncology at the Hospital Universitario 12 de Octubre in Madrid, Spain, and IMforte trial principal investigator. “These trial results demonstrate the efficacy of lurbinectedin, in combination with standard-of-care atezolizumab for patients in first-line maintenance treatment, a much-needed advancement for patients with extensive disease.”

“The results of the Phase 3 IMforte trial are highly encouraging and showed a statistically significant benefit for the lurbinectedin and atezolizumab combination for extensive-stage small cell lung cancer patients receiving this treatment in the first-line maintenance setting. These results demonstrate the potential of this regimen to delay disease progression and extend survival for patients with this aggressive disease,” said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development, and chief medical officer of Jazz Pharmaceuticals. “We are pleased with these clinically meaningful results and plan to submit an sNDA in the first half of 2025 to support this combination in the first-line maintenance setting. We thank the investigators and patients who are involved in this trial, along with our partners at Roche.“

“Lurbinectedin monotherapy is currently the standard of care in 2L SCLC. In Europe, it is only approved in Switzerland and early access and compassionate use programs have already allowed some European patients to benefit from lurbinectedin,” said Javier Jiménez, Chief Medical Officer of PharmaMar.

The combination was generally well-tolerated. The preliminary safety data in the ongoing trial is consistent with the known safety profiles of lurbinectedin and atezolizumab with no new safety signals observed in the combination arm.

Jazz and Roche plan to submit these data for presentation at a future medical meeting.

PharmaMar will submit a marketing authorisation application (MAA) to the EMA in the first half of 2025 to request regulatory approval in the European Union (EU). Lurbinectedin is available for use in 16 territories around the world.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation.

PharmaMar has developed and now commercializes Yondelis® in Europe by itself, as well as Zepzelca® (lurbinectedin), in the US; and Aplidin® (plitidepsin), in Australia, with different partners. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage programs under development for several types of solid cancers: lurbinectedin, ecubectedin, PM534 and PM54. Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland and The United States. PharmaMar also wholly owns Sylentis, a company dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

About the IMforte Phase 3 Trial

IMforte (NCT05091567) is an ongoing Phase 3, randomized, multicenter maintenance trial evaluating the efficacy, safety and pharmacokinetics of lurbinectedin plus atezolizumab in adults (≥18 years) with ES-SCLC following induction therapy with carboplatin, etoposide and atezolizumab. The primary endpoints for this study are OS and IRF-assessed PFS.

The trial consists of two phases: an induction phase and a maintenance phase. Participants were required to have an ongoing response or stable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 after the induction phase of four cycles of carboplatin, etoposide, and atezolizumab to be considered for eligibility screening for the maintenance phase. Eligible participants were randomized in a 1:1 ratio to receive either lurbinectedin plus atezolizumab or atezolizumab in the maintenance phase.

The trial is sponsored by Roche and co-funded by Jazz Pharmaceuticals. Additional information about the trial, including eligibility criteria and a list of clinical trial sites, can be found at: https://clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT05091567).

About Zepzelca^®

Zepzelca^® (lurbinectedin), also known as PM1183, is an analog of the marine compound ET-736 isolated from the sea squirt Ecteinascidia turbinata in which a hydrogen atom has been replaced by a methoxy group. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.

please visit our website at www.pharmamar.com

[i] Cancer today. (s. f.). https://gco.iarc.who.int/today/en/fact-sheets-populations#regions

[ii] Alvarado-Lunda G, Morales-Espinosa D. Treatment for small cell lung cancer, where are we now? – A review. Transl Lung Cancer Res. 2016;5(1):26-38.

[iii] SEER Explorer Lung and Bronchus Cancer, Recent Trends in SEER Incidence Rates, 2000-2016, by Age, https://seer.cancer.gov/explorer Updated June 27, 2024. Accessed October 10, 2024.

Photo – https://mma.prnewswire.com/media/2530990/PharmaMar.jpg
Logo – https://mma.prnewswire.com/media/2429111/PharmaMar_Logo.jpg